GlassScriptPhysician profile
Senad Osmanovic
NPI 1376869347
$3,796.41
in general payments reported to CMS, 2019-2025
28 companies · $880 in 2025
The $880 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $155 · 2020: $99.04 · 2021: $283 · 2022: $458 · 2023: $1,047 · 2024: $876 · 2025: $880.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,704 · Education: $97.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,704.45 |
| Education | $97.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $640.06 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $454.90 | 2019-2025 | Eylea Hd, Eylea |
| Alcon Vision LLC | $330.48 | 2022-2025 | Rocklatan, Hydrus Microstent, Tryptyr |
| Bausch & Lomb Americas INC. | $285.92 | 2022-2025 | Vyzulta, Lotemax Sm, Prolensa |
| Allergan, INC. | $265.78 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $261.46 | 2023-2025 | Acthar |
| Apellis Pharmaceuticals, INC. | $243.52 | 2023-2025 | Syfovre |
| Genentech USA, INC. | $233.05 | 2022-2025 | Vabysmo |
| Harrow Eye, LLC | $116.43 | 2023-2025 | Vevye |
| Novartis Pharmaceuticals Corporation | $112.98 | 2021-2023 | |
| Biotissue Holdings INC. | $110.73 | 2023 | |
| Alimera Sciences, INC. | $97.06 | 2019-2024 | Iluvien, Yutiq |
| Thea Pharma INC. | $94.05 | 2022-2024 | Iyuzeh |
| Ani Pharmaceuticals, INC. | $63.91 | 2025 | Purified Cortrophin Gel |
| Astellas Pharma US INC | $61.52 | 2023-2024 | Izervay |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $60.08 | 2024-2025 | Tepezza |
| Sun Pharmaceutical Industries INC. | $56.19 | 2023-2024 | Cequa |
| Aerie Pharmaceuticals, INC. | $44.37 | 2019 | |
| Eyevance Pharmaceuticals LLC | $37.19 | 2020-2021 | |
| Lkc Technologies, INC. | $36.95 | 2024 | |
| New World Medical,INC. | $34.82 | 2020-2025 | Kahook Dual Blade, Ahmed Glaucoma Valve, Streamline |
| Oyster Point Pharma, INC. | $24.82 | 2022 | |
| Akorn Operating Company LLC | $24.12 | 2021 | |
| Eyepoint US, INC. | $23.91 | 2023 | |
| Spark Therapeutics, INC. | $22.97 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $21.23 | 2020 | |
| Rxsight INC | $20.61 | 2025 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| Coherus Oncology, INC. | $17.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Senad Osmanovic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.